Myriad Genetics (MYGN) 10-Q2020 Q1 Quarterly report

Filed: 6 Nov 19, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accurate, Additionally, ADLT, Agency, arrangement, body, BRCA, Carolina, choose, classification, collateral, commencement, companion, country, digit, distracting, double, enhanced, Ethan, exclusive, fixed, Food, Fortune, gene, germline, growth, hindsight, identification, impairment, implicit, inception, indefinite, index, Japan, Justice, lengthy, list, low, master, men, monotherapy, monthly, myChoice, nature, niraparib, Noncurrent, OIG, olaparib, opted, outlook, package, parallel, payer, perspective, pharmacy, PMDA, Premarket, Prequel, proportionate, prostate, reassessing, recombination, renew, renewal, rent, resolved, review, ROU, scope, settle, settlement, significantly, Silverman, South, standing, supplementary, surveillance, Switzerland, Takeda, wrongdoing

Removed: American, April, bad, base, BEAT, binding, book, branch, breast, broad, care, classifying, comparability, compensated, constrained, contractor, controlled, converged, count, created, creating, dedicated, deductibility, deemed, depict, disposition, draft, effectively, eliminating, enacted, enactment, entity, environment, erosion, extent, failing, final, found, fully, government, impacted, importance, improper, improve, improvement, incomplete, insufficient, integration, International, January, Journal, Kessman, landmark, LCD, led, limit, limitation, local, making, Matthew, Medicaid, Melanoma, Meldrum, milestone, mutation, myPath, Noridian, objective, operational, personalized, Peter, Pfizer, play, preliminary, presenting, previously, primary, provisional, Psychiatric, recasting, receivable, Recently, reclassification, recording, reduce, reducing, relevant, relief, remediated, Repatriation, representing, requirement, restated, retrospectively, revaluing, reversal, revising, role, rule, SAB, satisfying, single, specifically, submitting, symptom, talazoparaib, targeted, taxable, taxation, temporary, transforming, treated, trial, ultimate, unclassified, unrepatriated, untaxed, upgrade, variant, waste, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated MYGN transcripts

MYGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Myriad Genetics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 5, 2019		Date: November 5, 2019
By:	/s/ Mark C. Capone	By:	/s/ R. Bryan Riggsbee
Mark C. Capone		R. Bryan Riggsbee
President and Chief Executive Officer		Executive Vice President, Chief Financial Officer